United Services Automobile Association decreased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 26,395 shares of the biopharmaceutical company’s stock after selling 795 shares during the period. United Services Automobile Association’s holdings in Alnylam Pharmaceuticals were worth $1,353,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. First Manhattan Co. bought a new stake in Alnylam Pharmaceuticals during the first quarter worth about $135,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $148,000. Westpac Banking Corp acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $202,000. Prudential Financial Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $215,000. Finally, Nisa Investment Advisors LLC acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $256,000. Institutional investors own 89.22% of the company’s stock.
Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) traded up 1.88% during trading on Friday, reaching $82.02. The company’s stock had a trading volume of 878,673 shares. The company’s market cap is $7.07 billion. The company’s 50 day moving average price is $78.15 and its 200 day moving average price is $57.51. Alnylam Pharmaceuticals, Inc. has a 52 week low of $31.38 and a 52 week high of $86.92.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.03. The business had revenue of $19 million for the quarter, compared to analyst estimates of $22.91 million. Alnylam Pharmaceuticals had a negative net margin of 705.11% and a negative return on equity of 42.90%. The firm’s quarterly revenue was up 160.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.21) earnings per share. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post ($5.24) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/07/22/united-services-automobile-association-has-1-35-million-stake-in-alnylam-pharmaceuticals-inc-alny-updated-updated-updated.html.
A number of research analysts have commented on ALNY shares. UBS AG started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, March 29th. They set a “neutral” rating and a $55.00 price target on the stock. BMO Capital Markets started coverage on Alnylam Pharmaceuticals in a research report on Monday, April 17th. They set an “outperform” rating and a $73.00 price target on the stock. Chardan Capital set a $95.00 target price on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 5th. Morgan Stanley raised their target price on Alnylam Pharmaceuticals from $39.00 to $42.00 and gave the company an “equal weight” rating in a research report on Monday, May 8th. Finally, Credit Suisse Group AG restated a “hold” rating and issued a $50.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 9th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $78.83.
In related news, major shareholder Sanofi bought 297,501 shares of the company’s stock in a transaction on Wednesday, May 31st. The shares were purchased at an average cost of $71.87 per share, for a total transaction of $21,381,396.87. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Akshay Vaishnaw sold 11,000 shares of the business’s stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total transaction of $825,000.00. Following the completion of the transaction, the executive vice president now owns 21,297 shares in the company, valued at $1,597,275. The disclosure for this sale can be found here. Insiders have sold 64,125 shares of company stock valued at $4,325,000 over the last quarter. Corporate insiders own 4.30% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.